Recommendation ID

The committee noted that there was no clinical evidence showing that having sodium zirconium cyclosilicate improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing sodium zirconium cyclosilicate plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate:

  • mortality
  • disease progression
  • patterns of RAAS inhibitor use
  • healthcare utilisation, and
  • health-related quality of life.
Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Sodium zirconium cyclosilicate for treating hyperkalaemia
Date issued
September 2019

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 30/09/2019